September was the third consecutive month in which the index barely moved month over month. NantHealth paced the gainers, while Quest Diagnostics paced the decliners.
The investment firm noted that Myriad is still trying to stabilize its hereditary cancer testing business while diversifying its portfolio to drive future growth.
During an earnings call, company executives discussed plans to grow reimbursement of new tests, stabilize pricing, and save costs through a number of projects.
